Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients.
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 190 participants.
Also called NCT02050529
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 190 participants
- Registry
-
NCT02050529
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Pakistan
- Registry status
- Completed
Technical summary
Registry record NCT02050529. Randomized; single masking; primary purpose treatment. Start 2012-10 (actual); primary completion 2014-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients.
- Condition
- Hypertension, Pregnancy Induced
- Condition
- Hydralazine Adverse Reaction
- Condition
- Pre-eclampsia
- Condition
- Pre-eclampsia Superimposed Pre-existing Hypertension
- Intervention (Drug)
- Labetalol
- Intervention (Drug)
- Hydralazine
- Lead sponsor
- Dow University of Health Sciences
Record details
- Record id
cardio:ct-nct02050529- Content hash
68b3880c8b231caf59f295b04875aae940f0f2820b15a9271629eec81b769421